2660 Patton Road
52 articles with Rebiotix
On May 1, the U.S. Food and Drug Administration (FDA) granted Scynexi’s oral formulation of SCY-078 to treat vulvovaginal candidiasis (VVC) and recurrent VVC both Qualified Infectious Diseases Product (QIDP) and Fast Track Designation.
Rebiotix Presents Posters at ECCMID 2018 Highlighting Microbiome Health Index™ Value Potential and RBX2660 Phase 2 Clinical Program Data
The posters add to the growing library of data recently published and presented by Rebiotix highlighting the company's microbiome drug products, clinical programs, and pioneering research involving microbiome composition and health.
Ferring Pharmaceuticals is buying Rebiotix. As part of the deal, will acquire Rebiotix’s lead program, RBX2660, a non-antibiotic treatment to prevent recurring Clostridium difficile infection (CDI).
Rebiotix’s RBX2660 is a non-antibiotic treatment in Phase 3 development for the prevention of recurrent Clostridium difficile infection (CDI) and has the potential to be the world’s first approved human microbiome product
Rebiotix's Chief Scientific Officer, Ken Blount, Ph.D., to Present at Microbiome Therapeutics Europe
Presentation to highlight clinical, regulatory and business opportunities in developing microbiome-directed therapeutics
Initial research indicates that Microbiome HealtMHI was established in partnership with data analytics firm, BioRankings, to enable a non-biased comparison of the efficacy of microbiome-based therapeutics.
Rebiotix provided a review of its 2017 key business achievements and clinical activities as the company anticipates multiple milestones during 2018 involving its industry-leading MRT drug platform.
Rebiotix and CoreBiome Collaborate on Evaluating Microbiomes of Patients Treated With Microbiota Restoration Therapy
Rebiotix, announced today its successful first phase of collaboration with CoreBiome to measure the ability of RBX2660 and RBX7455 to rehabilitate the human microbiome impacted by recurrent Clostridium difficile infection.
Rebiotix Announces Expansion of Phase I Trial of the Company's Oral Capsule Microbiota Product, RBX7455, Following Successful Completion of Initial Study Arms
The expansion follows the successful completion of the study's two initial cohorts and is intended to explore reduced dosing regimens of RBX7455 in two new treatment arms.
New Clinical Data And Microbiome Research From Rebiotix's Phase II Program For RBX2660 Highlighted At The World Congress Of Gastroenterology At ACG2017
Rebiotix today announced new clinical findings from the RBX2660 Phase 2 program that are being presented in three poster presentations at the World Congress of Gastroenterology at ACG2017 in Orlando, Fl.
Rebiotix Announces First Patient Enrolled In Phase III Clinical Trial Of RBX2660 For The Prevention Of Recurrent Clostridium Difficile Infection
Rebiotix Continues Management Team Expansion With Appointment Of Greg Fluet As Chief Business Officer
Rebiotix Data Presented At ASM Microbe 2017 Show RBX2660 Treated Patients' Clinical Success Correlates With Improved Microbiome Diversity
Rebiotix Reports Positive Top Line Data From Open-Label Phase II Trial Of RBX2660 In Recurrent Clostridium Difficile
Rebiotix Treats First Patient In Phase 1 Study Of RBX7455, An Orally Delivered Broad-Spectrum Non-Frozen Microbiota Capsule For Recurrent Clostridium Difficile Infection